Tyler Xiu

Tyler’s practice encompasses various aspects of transactional, regulatory, and contentious IP matters including technology transfer and licensing, IP and data-driven strategic cooperation, technical services and outsourcing arrangements, technology/IP-related advice in cross-border M&A and PE transactions, cybersecurity and data privacy, telecommunications regulation, pharmaceutical regulation, and patent protection. He advises a diverse range of multinational companies mainly in the life sciences, IT, telecommunications, manufacturing, and financial industries. In the words of his clients, “Tyler Xiu is an excellent up-and-coming lawyer, who is very proactive and helpful.” (The Legal 500 Asia Pacific).

Tyler is fluent in Chinese and English.

Representative Experience

• Advising Ensem Therapeutics, Inc., a biotechnology company focusing on high value and difficult-to-drug oncology targets, on its partnership with BeiGene, Ltd., a global biotechnology company, for BeiGene to acquire an exclusive global license to an Investigational New Drug (IND) application-ready oral cyclin-dependent kinase 2 (CDK2) inhibitor. Under the terms of the agreement, ENSEM will receive an upfront payment, and will be eligible for additional payments upon the achievement of certain development, regulatory, and commercial milestones, totaling up to $1.33 billion, in addition to tiered royalties.
• Advising Jamieson Laboratories Ltd. and its parent company Jamieson Wellness Inc. (TSX:JWEL) in their partnership with DCP Capital, a leading international private equity firm founded by experienced private equity investors in Greater China. Through this transaction, DCP contributed US$35 million in exchange for a 33% interest in the Company’s Chinese operations and made a US$75 million preferred share investment in the Company.
• Counseling a U.S. medical device company that focuses on the research, development, production, and marketing of respiratory care devices and services, in its engagement by a PRC medical device company for commissioned development of automatic high flow ventilators, including the associated technology licensing arrangements.
• Advising a U.S. biopharmaceutical company on its strategic collaboration with a Chinese pharmaceutical company to develop and commercialize a bi-functional fusion protein inhibiting immune checkpoint and activating natural killer (NK) cells for the treatment of solid tumors, in the Asia Pacific Ex-Japan region.
• Advising a leading pan-Asian retailer in Hong Kong on:
  • A technology license agreement and joint venture with a digital retail platform for the purposes of providing online retailers with operational processes, marketing, supply, payment, merchandise, e-commerce, and customer services; and
  • Its licensing of technology and trademarks and provision of technical services in relation to the establishment of a joint venture for the purposes of developing a market-leading independent multi-partner coalition loyalty program for the ASEAN markets, and also the data privacy and data security issues under PRC law and cross-border data transfer issues that involve multiple jurisdictions in Asia.